| Popis: |
Introduction: Latino youth are disproportionately impacted by prediabetes and type 2 diabetes (T2D) . Lifestyle intervention is the first line approach for preventing or delaying T2D among adults with prediabetes. We assessed the efficacy of a diabetes prevention program among Latino youth with prediabetes. Methods: A total of 117 Latino youth (mean±SD, age 13.5±1.4) with prediabetes and obesity were randomized to lifestyle intervention (INT) or usual care (UC) . The 6-month INT (n=79) included 1 d/wk of nutrition education and training and 3 d/wk of physical activity. UC (n=38) included 2 visits with a pediatric endocrinologist and registered dietitian to discuss diabetes risks and healthy lifestyle changes. A 75-g oral glucose tolerance test was used to assess glucose tolerance (2-h glucose) , insulin sensitivity (Matsuda Index) , and β-cell function (oral disposition index, oDI) at baseline, 6 months, and 12 months. Changes in outcomes were analyzed using latent difference scores models. Results: The INT led to significant decreases in 2-h glucose (mean±SE, from 144.5±3.4 to 132.2±3.4 mg/dL, p=0.002) and increases in insulin sensitivity (from 1.9±0.2 to 2.6±0.3, p=0.001) and oDI (from 4.5±0.3 to 5.5±0.4, p=0.035) at 6 months, but these changes were not significantly different from UC (interaction, p=0.260, p=0.79, and p=0.78, respectively) . Both INT (-15.4 mg/dL, p=0.002) and UC (-15.1 mg/dL, p=0.005) had significant 12-month reductions in 2-h glucose that did not differ significantly from each other (interaction, p=0.97) . INT led to significant increases in oDI (from 4.5±0.3 to 6.2±0.6, p=0.035) and non-significant increases in insulin sensitivity (from 1.9±0.2 to 2.3±0.2, p=0.060) at 12 months that did not differ from UC (interaction, p=0.66 and p=0.37, respectively) . Conclusion: Both INT and UC led to similar changes in T2D risk factors among high risk Latino youth. Diabetes prevention interventions that are effective in adults also appear to be effective in high risk youth. Disclosure A. Pena: None. M. Olson: None. S. Ayers: None. D.L. Patrick: Consultant; Allakos, Bristol-Myers Squibb Company, Grail, Philip Morris. F.G. Castro: None. E. Lish: None. W.C. Knowler: None. G.Q. Shaibi: None. Funding R01DK107579F31DK125037 |
